Determining Patient Selection for CAR T-Cell Therapy in Multiple Myeloma With Beth Faiman, PhD, CNP
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Determining Patient Selection for CAR T-Cell Therapy in Multiple Myeloma With Beth Faiman, PhD, CNP While chimeric antigen receptor (CAR) T–cell therapy has revolutionized the treatment landscape for multiple myeloma, the high demand for these efficacious therapies has made patient selection a challenge. At the recent International Myeloma Society Annual Meeting, Beth Faiman, a Nurse Practitioner at the Cleveland Clinic, presented a poster about a clinical factor scoring system that she and her colleagues have developed to aid in these decisions. In this follow-up interview with Oncology Data Advisor, Dr. Faiman explains how this innovative system works and the next steps to validate it and implement it into practice in the future.  
Addressing Clinical Trial Accrual of Minority Patients With Donna Catamero, NP
Lyn Brook
Expert Analysis
At the recent International Myeloma Society (IMS) Annual Meeting, Donna Catamero, NP, the Associate Director of Myeloma Translational Research at Mount Sinai Hospital, presented her abstract regarding increasing clinical trial accrual of minority patients. In this interview, Ms. Catamero discusses her presentation, the disproportionate burden that minority patients experience, and why she believes the health care team should take action to create an equal space for everyone in the clinic.  
Caring for Patients Receiving CAR T-Cell Therapy With Joshua Sasine, MD, PhD
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Dr. Joshua Sasine, Hematologist-Oncologist at Cedars-Sinai Medical Center, discusses the factors that make patients suitable candidates for chimeric antigen receptor (CAR) T-cell therapy, strategies to minimize the unique toxicities associated with these treatments, and the future of the use of CAR T-cell therapy in the outpatient setting.  
Determining Patient Selection for CAR T-Cell Therapy in Multiple Myeloma With Beth Faiman, PhD, CNP
Keira Smith
Expert Analysis
While chimeric antigen receptor (CAR) T–cell therapy has revolutionized the treatment landscape for multiple myeloma, the high demand for these efficacious therapies has made patient selection a challenge. At the recent International Myeloma Society Annual Meeting, Beth Faiman, a Nurse Practitioner at the Cleveland Clinic, presented a poster about a clinical factor scoring system that she and her colleagues have developed to aid in these decisions. In this follow-up interview with Oncology Data Advisor, Dr. Faiman explains how this innovative system works and the next steps to validate it and implement it into practice in the future.  
No One Left Alone: Taking the First Steps to Address Cancer Disparities With Kashyap Patel, MD
Keira Smith
Expert Analysis
At the recent International Myeloma Society (IMS) Annual Meeting, Dr. Kashyap Patel, CEO of Carolina Blood and Cancer Care Associates and President of the Community Oncology Alliance, spoke about practical solutions for addressing disparities in multiple myeloma in the United States. In this follow-up interview with Oncology Data Advisor, Dr. Patel digs deep into the multifaceted factors that contribute to cancer disparities and shares his pioneering work that aims to ensure that every patient with cancer receives equitable access to care.  
Significant Knowledge Gains Acquired for Treating Metastatic Breast Cancer
Lyn Brook
Practice Patterns
An educational enduring online activity provided by i3 Health has provided knowledge gains pertaining to enhancing treatment tolerability, adherence, and patient-centered care for metastatic breast cancer. In the United States, breast cancer accounts for approximately 30% of cancer diagnoses among women and is the second-leading cause of cancer dea...
Staying Up to Date on Endometrial Cancer With Ritu Salani, MD
Lyn Brook
Expert Analysis
Cancer of the uterine corpus, also called endometrial cancer, is the most common cancer of the female genital tract, with the American Cancer Society estimating that there will be 65,950 new diagnoses and 12,550 fatal cases in the United States in 2022. In this interview, Ritu Salani, MD, Director of the Division of Gynecologic Oncology at the University of California, Los Angeles (UCLA) Health, touches base on a recent activity she led, Emerging Checkpoint Inhibitor-Based Strategies for Advanced Endometrial Cancer. In addition, she discusses updates since recording the activity and why it's important for health care professionals to participate in staying up to date with the evolving landscape of endometrial cancer treatment options.  
The Future of MRD in Multiple Myeloma Treatment Decision Making With Rahul Banerjee, MD, and Ben Derman, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · The Future of MRD in Multiple Myeloma Treatment Decision Making In this interview, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee speaks with Dr. Ben Derman, Assistant Professor of Medicine at the University of Chicago, about his research regarding measurable residual disease (MRD) detection in multiple myeloma and its potential role in guiding treatment decisions.  
Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace™, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.  
The Future of MRD in Multiple Myeloma Treatment Decision Making With Rahul Banerjee, MD, and Ben Derman, MD
Keira Smith
Expert Analysis
In this interview, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee speaks with Dr. Ben Derman, Assistant Professor of Medicine at the University of Chicago, about his research regarding measurable residual disease (MRD) detection in multiple myeloma and its potential role in guiding treatment decisions.  
Understanding the Current Landscape of Chemotherapy-Induced Neutropenia With Maura Abbott, NP, MSN, PhD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Understanding the Current Landscape of Chemotherapy-Induced Neutropenia Chemotherapy-induced neutropenia (CIN) is a common and potentially life-threatening consequence of chemotherapy, as it may lead to serious infections for patients with cancer. These infections result in hospital stays, increased morbidity and mortality, and considerable financial burden. In this interview, Dr. Maura Abbott explains the importance of managing and educating patients about CIN.  
World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.  
Providing Proficiency for Personalized Care Plans for Metastatic Colorectal Cancer
Lyn Brook
Practice Patterns
An educational enduring online activity provided by i3 Health has demonstrated knowledge gains pertaining to up-to-date treatment and personalized health care plans for metastatic colorectal cancer (CRC). Recently the American Cancer Society estimated that CRC would see 151,030 new cases, with 52,580 of these diagnoses being fatal, this year alone,...
Understanding the Research on Novel Treatments and Nutritional Interventions for Multiple Myeloma With Urvi Shah, MD
Keira Smith
Expert Analysis
During the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Urvi Shah from Memorial Sloan Kettering Cancer Center sat down with Oncology Data Advisor to share her perspectives on the exciting research that was presented in the poster discussion session she chaired on novel therapies for multiple myeloma. In addition, Dr. Shah explains more about her work to impact patients' quality of life and outcomes through nutritional interventions.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 
World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD
Keira Smith
Expert Analysis
On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.  
Understanding the Current Landscape of Chemotherapy-Induced Neutropenia With Maura Abbott, NP, MSN, PhD
Lyn Brook
Expert Analysis
Chemotherapy-induced neutropenia (CIN) is a common and potentially life-threatening consequence of chemotherapy, as it may lead to serious infections for patients with cancer. These infections result in hospital stays, increased morbidity and mortality, and considerable financial burden. In this interview, Dr. Maura Abbott explains the importance of managing and educating patients about CIN.  
Epic Experiences Available for Cancer Survivors With Colin Ferro
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Thriving Beyond the Cancer Diagnosis: Colin Ferro At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Colin Ferro, Director of Operations at Epic Experience, spoke with Oncology Data Advisor about the organization's mission to empower adult cancer survivors and thrivers beyond their diagnosis and treatment. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 
Understanding Antibody-Drug Conjugates and Their Use in the Treatment of Breast Cancer With Ian Krop, MD, PhD
Elizabeth Heller, PhD
Expert Analysis
Oncology Data Advisor™ · Patritumab Deruxtecan for HER3-Expressing Metastatic Breast Cancer: Ian Krop, MD, PhD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Ian Krop, Director of the Yale Cancer Center Clinical Trials Office, sat down with Oncology Data Advisor to discuss his research and the data he presented regarding the HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) for treatment of metastatic breast cancer.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMED.  
Accomplishing Knowledge Gains in the Diagnosis and Management of Myelodysplastic Syndromes
Eden Maack
Practice Patterns
A learning opportunity provided by i3 Health has demonstrated significant knowledge gains regarding the latest advances in the treatment of myelodysplastic syndromes. These findings were presented at the 4th Annual Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit.
Changing the Standard of Care for Pediatric Neuroblastoma With Wendy London, PhD
Elizabeth Heller, PhD
Expert Analysis
Oncology Data Advisor™ · Neuroblastoma Risk Stratification and Research: Wendy London, PhD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Wendy London, Associate Professor of Pediatrics at Harvard Medical School, sat down with Oncology Data Advisor to share her research regarding risk stratification, reduction of therapy, and survival outcomes for pediatric patients with neuroblastoma. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.

Copyright © 2022 Oncology Data Advisor. All rights reserved.